Castle Biosciences, Inc. (CSTL) vs Fulgent Genetics, Inc. (FLGT)

Castle Biosciences, Inc. and Fulgent Genetics, Inc. are both Diagnostics & Research companies. Castle Biosciences, Inc. is the larger, with a market value of $1.1B against $593.0M — 1.8× the size. Fulgent Genetics, Inc. grew revenue faster over the last twelve months: 6.83% against 3.18%. Castle Biosciences, Inc. has the higher net margin (−5.43% vs −26.1%) and the higher return on invested capital (−9.40% vs −10.3%). Across the 18 metrics below, Castle Biosciences, Inc. leads on 10 and Fulgent Genetics, Inc. on 8.

Valuation

Metric CSTL FLGT Diagnostics & Research median
P/E n/m n/m 33.95
P/S 3.03 1.92 4.87
P/B 2.30 0.62 3.12
Price to free cash flow n/m n/m 34.02
EV/EBITDA n/m n/m 25.20
EV/Sales 2.31 1.18 5.66
Earnings yield (1.85%) (12.70%) (1.75%)
Free cash flow yield (0.04%) (16.69%) (0.13%)

Profitability

Metric CSTL FLGT Diagnostics & Research median
Gross margin 77.26% 35.58% 50.89%
Operating margin (8.99%) (37.75%) (8.57%)
Net margin (5.43%) (26.05%) (6.37%)
Free cash flow margin (0.13%) (32.04%) 0.00%
Return on equity (4.20%) (8.01%) (2.92%)
Return on assets (3.51%) (7.37%) (6.71%)
Return on invested capital (9.40%) (10.34%) 0.00%

Growth

Metric CSTL FLGT Diagnostics & Research median
Revenue growth (TTM) 3.18% 6.83% 7.69%
EPS growth (last fiscal year) (233.87%) (39.72%) —
Revenue growth, 5-year CAGR 40.60% (5.21%) 7.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CSTL FLGT Diagnostics & Research median
Debt to equity 0.02 0.00 0.11
Current ratio 6.04 6.34 2.02
Net debt to EBITDA 46.20 4.66 0.78

Dividend

Metric CSTL FLGT Diagnostics & Research median
Dividend yield — — 0.70%
Payout ratio 0.00 0.00 0.00

Size

Metric CSTL FLGT Diagnostics & Research median
Market cap 1.08b 592.95m 2.56b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack